Global Burden of Disease (GBD) for Hepatitis C

Journal of Clinical Pharmacology - Tập 44 Số 1 - Trang 20-29 - 2004

Tóm tắt

Hepatitis C virus (HCV) infection is now a global public health issue. However, the global burden of disease attributable to HCV infection is unknown. The objectives of this WHO informal consultation included the following: (1) defining a strategy to estimate the global burden of disease (GBD) associated with HCV infection in terms of morbidity and mortality, (2) describing the natural history of HCV infection in terms of morbidity and mortality, and (3) identifying areas for which more research is needed. The GBD project is an attempt to examine all causes of morbidity and mortality using an approach common to all conditions. The World Health Organization (WHO) already has estimated the burden of disease associated with hepatitis B virus (HBV) infection and is now about to conduct the same analysis for HCV infection. A review has been conducted to estimate the prevalence of HCV infection by age, gender, and region. These figures can be used to estimate incidence, although there are a number of areas of uncertainty. Combined with natural history parameters, incidence estimates could be used to estimate the future burden due to current infections. However, the present model is not validated and requires calibration before it can be used. A consensus was reached over the strategies to be used to (1) estimate the current burden due to past infections and (2) estimate the future burden due to current infections. Provisional expert consensus was reached over natural history parameters and cofactors that influence them. However, systematic literature reviews and meta‐analysis are preferable for obtaining estimates to be included in models. Areas deserving future research include (1) obtaining a better estimate of HCV infection prevalence by age groups, (2) characterizing the various morbidity states associated with HCV infection and their disability weights, (3) understanding the long‐term natural history of HCV infection beyond 20 years after infection, and (4) estimating the prevalence (and numbers of) of HCV infection among the drug‐using population worldwide. A working group was created to address unmet needs and to assist the WHO in estimating the GBD associated with HCV infection.

Từ khóa


Tài liệu tham khảo

10.3109/00365529209011189

10.1053/jhep.2001.27831

10.1016/S0168-8278(00)00097-0

10.1046/j.1440-1746.2002.02730.x

10.1097/00042737-200201000-00006

10.1002/cncr.10662

10.1111/j.1440-1746.1996.tb00278.x

10.1053/jhep.2000.20456

10.1056/NEJM198911303212202

10.1056/NEJM199111073251901

Dore G, 2001, Hepatitis C: An Australian Perspective, 82

10.1053/gast.1997.v112.pm9024300

10.1002/hep.510270535

10.1002/hep.510250344

10.1056/NEJM199109053251002

10.1053/jhep.2001.21041

10.2105/AJPH.90.10.1562

10.7326/0003-4819-131-3-199908030-00003

10.1002/hep.1840180109

10.1002/hep.1840120411

PowellEE:How host and viral factors affect fibrosis progression in HCV. Paper presented at the 3rd Australasian Conference on Hepatitis C Melbourne Australia 2002.

10.1002/hep.510290401

10.1053/jhep.2001.24432

10.1136/gut.51.1.89

10.1007/BF01691375

Dore G, 1998, HIV and hepatitis C coinfection

10.1111/j.1365-2893.1997.tb00183.x

10.1002/hep.510280330

10.7326/0003-4819-134-2-200101160-00012

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 44 Số 1

20-29

Thông tin tác giả